COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Changes in Breast 3D Ultrasound Measurements Using Toremifene

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01417754
Recruitment Status : Completed
First Posted : August 16, 2011
Last Update Posted : August 23, 2011
Tampere University Hospital
Tampere University
Information provided by (Responsible Party):
SINIKKA OKSA, Satakunta Central Hospital

Brief Summary:
To investigate if there are detectable changes in volume and circulation in breasts of healthy volunteers using toremifene 20 mg in luteal phase of the menstruation cycle versus nonmedicated cycle.

Condition or disease Intervention/treatment Phase
Circulatory; Change Drug: Toremifene Phase 3

Detailed Description:
20 women were participated to this trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Volume and Circulation Changes of The Breast in 3D Ultrasound During Toremifene Versus Nonmedicated Menstrual Cycle
Study Start Date : September 2010
Actual Primary Completion Date : November 2010
Actual Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Toremifene Drug: Toremifene
20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
Other Name: trade name Fareston

Primary Outcome Measures :
  1. circulation changes of the breast [ Time Frame: cycle day 23 to 26 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • age 25-45 healthy person
  • regular menstrual cycles
  • safe contraception(for example sterilization or condom)

Exclusion Criteria:

  • gynecological or other type of cancer
  • hormonal contraception
  • pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01417754

Layout table for location information
Porin Lääkäritalo
Pori, Finland, 28100
Sponsors and Collaborators
Satakunta Central Hospital
Tampere University Hospital
Tampere University
Layout table for investigator information
Principal Investigator: Sinikka Oksa, MD Satakunta Central Hospital
Study Director: Johanna Mäenpää, professor Tampere University Hospital
Layout table for additonal information
Responsible Party: SINIKKA OKSA, MD, principal investigator, Satakunta Central Hospital Identifier: NCT01417754    
Other Study ID Numbers: Tore3D
First Posted: August 16, 2011    Key Record Dates
Last Update Posted: August 23, 2011
Last Verified: August 2011
Keywords provided by SINIKKA OKSA, Satakunta Central Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Bone Density Conservation Agents